Skip to main content
NGLFINE · Health Care · 2026-08-21

Ngl Fine Chem Ltd

6.2★ FairStrong +6.9Stage 2 · wk 29In scan: Prop Scan · Pullback HunterMARKET: BULL RISING · 2026-08-21
₹2,947.7
-2.82% today
₹1,821 Cr · Small cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Visit company website →
P/E (TTM)
47.1
Forward —
Earnings Growth (YoY)
+1539.8%
Revenue +57.2%
ROE
+15.7%
Profit margin +9.6%
Dividend Yield
0.06%
P/B 5.6
vs 52W High
-14.8%
₹1,278.8 lo₹3,457.8 hi
14.8% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 29
1w13w26w
Week 29 — mature, watch for distribution
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
30.7%
200 DMA: ₹2,254.6 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.37x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 gently rising · +0.9% vs MA50 +8.8%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #6 of 84 Stage 2 stocks in Health Care by RS. Leading the sector.
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Ranks #6 of 58 Stage 2 stocks in this industry. Top tier.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-29 → 2026-08-21
S2 16w
S2 26w
S4 32w
S2 29w
2023-05-292026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 3w → S2 16w → S3 9w → S2 9w → S3 2w → S2 26w → S3 5w → S4 32w → S1 3w → S4 3w → S1 10w → S2 10w → S3 9w → S2 29w current
Total tracked: 168 weeks across 14 stage runs.
1M
-7.8%
3M
+7.7%
6M
+28.8%
YTD
+127.6%
1Y
+122.9%
Scan Membership
Prop Scan
Latest: 2026-08-14
Pullback Hunter
Latest: 2026-07-20
60 appearances in last 60 days. First seen: 2026-06-15.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 29 · Vol x
2026-08-20S2
Wk 28 · Vol x
2026-08-19S2
Wk 28 · Vol x
2026-08-18S2
Wk 28 · Vol x
2026-08-17S2
Wk 28 · Vol x
2026-08-14S2
Wk 28 · Vol x
2026-08-13S2
Wk 27 · Vol x
2026-08-12S2
Wk 27 · Vol x
2026-08-11S2
Wk 27 · Vol x
2026-08-10S2
Wk 27 · Vol x
2026-08-07S2
Wk 27 · Vol x
2026-08-06S2
Wk 26 · Vol x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹3,170.5
200 DMA
₹2,254.6
52W High
₹3,457.8
52W Low
₹1,278.8
5D Low
₹2,908.4
Resistance levels (recent highs)
20d High
₹3,457.8
60d High
₹3,457.8
120d High
₹3,457.8
250d High
₹3,457.8
Next resistance
+17.3%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.